2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
58
Leukemia
52
Lymphoma
37
Myelodysplastic Syndromes
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Lymphoma, Non-Hodgkin
22
Hodgkin Disease
22
Leukemia, Myeloid, Acute
18
Multiple Myeloma
17
Myeloproliferative Disorders
14
Recurrence
12
Lymphoma, Mantle-Cell
12
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, T-Cell, Peripheral
10
Lymphoma, Follicular
10
Congenital Abnormalities
10
Neoplasms, Plasma Cell
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myeloid, Chronic-Phase
9
Hematologic Neoplasms
9
Burkitt Lymphoma
9
Anemia, Aplastic
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Waldenstrom Macroglobulinemia
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, T-Cell
7
Lymphoma, Large-Cell, Immunoblastic
7
Graft vs Host Disease
7
Sezary Syndrome
6
Primary Myelofibrosis
6
Interventions
pembrolizumab
24
Nivolumab
23
aldesleukin
21
Cyclophosphamide
20
Ipilimumab
17
Interleukin-2
17
fludarabine
15
fludarabine phosphate
14
cemiplimab
12
Radiotherapy
7
Fluorouracil
7
Biopsy
7
dabrafenib
6
Surveys and Questionnaires
6
Dacarbazine
6
trametinib
5
binimetinib
5
Vemurafenib
5
Temozolomide
5
Surgical Procedures, Operative
5
Sirolimus
5
Radiation
5
Blood Specimen Collection
5
Aminolevulinic Acid
5
sonidegib
4
encorafenib
4
Photochemotherapy
4
Mohs Surgery
4
HhAntag691
4
Educational Status
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
Alemtuzumab
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled